Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caterina Alati

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Cancers|October 16, 2024
First-Line Use of Daratumumab in Patients with Multiple Myeloma Shows Delayed Neutrophil and Platelet Engraftment after Autologous Stem Cell Transplantation: Results from a Real-Life Single-Center StudyMassimo Martino, Mercedes Gori, Gaetana Porto, et al.
Annals of Hematology|April 20, 2023
Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantationMassimo Martino, Mercedes Gori, Gaetana Porto, et al.
Cancers|May 13, 2023
Azacitidine Post-Remission Therapy for Elderly Patients with AML: A Randomized Phase-3 Trial (QoLESS AZA-AMLE)Esther Natalie Oliva, Anna Candoni, Prassede Salutari, et al.
International Journal of Molecular Sciences|November 9, 2024
Translational Research on Azacitidine Post-Remission Therapy of Acute Myeloid Leukemia in Elderly Patients (QOL-ONE Trans-2)Esther Natalie Oliva, Maria Cuzzola, Matteo Della Porta, et al.
The Lancet. Haematology|February 7, 2017
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trialEsther N Oliva, Caterina Alati, Valeria Santini, et al.
The Lancet. Haematology|September 23, 2024
Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trialDomenico Russo, Nicola Polverelli, Simona Bernardi, et al.
Blood Cancer Journal|October 7, 2020
CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use programFabio Guolo, Luana Fianchi, Paola Minetto, et al.
Blood|August 10, 2019
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemiaAdriano Venditti, Alfonso Piciocchi, Anna Candoni, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 19, 2026
Treatment of Acute Myeloid Leukemias and Myelodisplastic Syndromes Relapsing After Allogeneic Stem Cell Transplantation: An In-Depth Analysis of the GITMO AML/MDS-Relapse Registry StudyMichele Malagola, Domenica Matranga, Luca Castagna, et al.
Expert Opinion on Biological Therapy|August 31, 2021
Identifying and managing CAR T-cell-mediated toxicities: on behalf of an Italian CAR-T multidisciplinary teamMassimo Martino, Sebastiano Macheda, Umberto Aguglia, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Cancers|October 16, 2024
First-Line Use of Daratumumab in Patients with Multiple Myeloma Shows Delayed Neutrophil and Platelet Engraftment after Autologous Stem Cell Transplantation: Results from a Real-Life Single-Center StudyMassimo Martino, Mercedes Gori, Gaetana Porto, et al.
Annals of Hematology|April 20, 2023
Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantationMassimo Martino, Mercedes Gori, Gaetana Porto, et al.
Cancers|May 13, 2023
Azacitidine Post-Remission Therapy for Elderly Patients with AML: A Randomized Phase-3 Trial (QoLESS AZA-AMLE)Esther Natalie Oliva, Anna Candoni, Prassede Salutari, et al.
International Journal of Molecular Sciences|November 9, 2024
Translational Research on Azacitidine Post-Remission Therapy of Acute Myeloid Leukemia in Elderly Patients (QOL-ONE Trans-2)Esther Natalie Oliva, Maria Cuzzola, Matteo Della Porta, et al.
The Lancet. Haematology|February 7, 2017
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trialEsther N Oliva, Caterina Alati, Valeria Santini, et al.
The Lancet. Haematology|September 23, 2024
Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trialDomenico Russo, Nicola Polverelli, Simona Bernardi, et al.
Blood Cancer Journal|October 7, 2020
CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use programFabio Guolo, Luana Fianchi, Paola Minetto, et al.
Blood|August 10, 2019
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemiaAdriano Venditti, Alfonso Piciocchi, Anna Candoni, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 19, 2026
Treatment of Acute Myeloid Leukemias and Myelodisplastic Syndromes Relapsing After Allogeneic Stem Cell Transplantation: An In-Depth Analysis of the GITMO AML/MDS-Relapse Registry StudyMichele Malagola, Domenica Matranga, Luca Castagna, et al.
Expert Opinion on Biological Therapy|August 31, 2021
Identifying and managing CAR T-cell-mediated toxicities: on behalf of an Italian CAR-T multidisciplinary teamMassimo Martino, Sebastiano Macheda, Umberto Aguglia, et al.
Pageof 5